We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Siemens Healthineers and Primary Health Care Enter Contract for In Vitro Diagnostics

By LabMedica International staff writers
Posted on 12 Nov 2018
Print article
Image: The Atellica Solution immunoassay and clinical chemistry analyzers (Photo courtesy of Siemens Healthineers).
Image: The Atellica Solution immunoassay and clinical chemistry analyzers (Photo courtesy of Siemens Healthineers).
Siemens Healthineers (Erlangen, Germany) has entered into a strategic partnership with Australian integrated healthcare provider Primary Health Care to deploy more than 70 Atellica Solution immunoassay and clinical chemistry analyzers, marking the largest contract ever for in vitro diagnostics testing in the country.

The analyzers are integrated with Atellica Diagnostics IT solutions and will connect to the company’s strategic partner Inpeco’s FlexLab track for total lab automation to deliver a high throughput multi-disciplinary solution with capabilities that are transforming the clinical laboratory landscape across Australia.

Siemens Healthineers offers a wide portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Primary Health Care has a large presence in all mainland states in Australia with one in every three pathology samples taken in the country being tested in a Primary laboratory. The Siemens Healthineers technology will be rolled out in New South Wales, Queensland, Victoria and Western Australia.

The strategic engagement couples Primary’s expansive network of more than 2,300 national pathology collection sites with workflow improvement and expanded clinical capabilities from Siemens Healthineers to establish a new level of automated diagnostic delivery. Through deep analytics, and intelligent data and process management, Atellica Diagnostics IT software will provide Primary with improved visibility, flexibility and control over its entire operation. Siemens Healthineers and Inpeco SA will deliver this fully automated multidisciplinary solution that will vastly simplify clinical and operational workflows and help Primary achieve better outcomes at much lower costs.

“With the introduction of the Atellica Solution and the complementary, innovative offering of Atellica Diagnostics IT, we’ll turn what has been more than a decade of collaboration with Primary Health Care into an entirely new frontier for the Australian pathology industry,” said Sebastian D’Angelo, General Manager, Laboratory Diagnostics, Australia, Siemens Healthineers.

“This new collaboration will allow us to take Primary’s operational efficiencies to new heights,” said Wes Lawrence, Chief Executive of Pathology at Primary Health Care. “Thanks to this next-generation technology, we’re able to increase productivity, and focus more on value-adding lab activities and less on sample and instrument handling. In doing so, processes will be reduced and testing quality will be advanced, ultimately helping us increase cost savings and focus on the human impact of our work.”

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
HbA1c Test
HbA1c Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.